Strike Pharma is a Swedish biotech company developing in vivo CAR-T therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery
Learn more about our Technology, Pipeline and Disease indications, and see our Publications and posters.
Latest News
Per Norlén joins Strike Pharma as new CEO
Strike Pharma, (“Strike”) a Swedish biotech with a novel technology for antibody-drug conjugation, has announced the appointment of Dr Per Norlén, MD PhD, as new CEO. Dr Norlén brings more than 20 years of clinical and commercial experience from leading positions within big pharma and biotech.
Latest Events
Strike Pharma presents further developments at CICON23
Scientists from Strike Pharma presented two scientific posters demonstrating progress in the preclinical development of STRIKE2001-KRAS and in the use of the ADAC technology platform for drug cargo delivery.
Strike Pharma presents latest developments at AACR 2023
Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.
Strike Pharma, Uppsala University and KTH Royal Institute of Technology present at CIMT 2022
CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation